Shmeylan A Al Harbi, Mohammad Khedr, Hasan M Al-Dorzi, Haytham M Tlayjeh, Asgar H Rishu, Yaseen M Arabi
{"title":"重症监护病房期间他汀类药物治疗与静脉血栓栓塞发生率之间的关系:倾向评分调整分析。","authors":"Shmeylan A Al Harbi, Mohammad Khedr, Hasan M Al-Dorzi, Haytham M Tlayjeh, Asgar H Rishu, Yaseen M Arabi","doi":"10.1186/2050-6511-14-57","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Studies have shown that statins have pleiotropic effects on inflammation and coagulation; which may affect the risk of developing venous thromboembolism (VTE). The objective of this study was to evaluate the association between statin therapy during intensive care unit (ICU) stay and the incidence of VTE in critically ill patients.</p><p><strong>Methods: </strong>This was a post-hoc analysis of a prospective observational cohort study of patients admitted to the intensive care unit between July 2006 and January 2008 at a tertiary care medical center. The primary endpoint was the incidence of VTE during ICU stay up to 30 days. Secondary endpoint was overall 30-day hospital mortality. Propensity score was used to adjust for clinically and statistically relevant variables.</p><p><strong>Results: </strong>Of the 798 patients included in the original study, 123 patients (15.4%) received statins during their ICU stay. Survival analysis for VTE risk showed that statin therapy was not associated with a reduction of VTE incidence (crude hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.28-1.54, P=0.33 and adjusted HR 0.63, 95% CI 0.25-1.57, P=0.33). Furthermore, survival analysis for hospital mortality showed that statin therapy was not associated with a reduction in hospital mortality (crude HR 1.26, 95% CI 0.95-1.68, P=0.10 and adjusted HR 0.98, 95% CI 0.72-1.36, P=0.94).</p><p><strong>Conclusion: </strong>Our study showed no statistically significant association between statin therapy and VTE risk in critically ill patients. This question needs to be further studied in randomized control trials.</p>","PeriodicalId":48846,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"14 ","pages":"57"},"PeriodicalIF":2.9000,"publicationDate":"2013-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/2050-6511-14-57","citationCount":"2","resultStr":"{\"title\":\"The association between statin therapy during intensive care unit stay and the incidence of venous thromboembolism: a propensity score-adjusted analysis.\",\"authors\":\"Shmeylan A Al Harbi, Mohammad Khedr, Hasan M Al-Dorzi, Haytham M Tlayjeh, Asgar H Rishu, Yaseen M Arabi\",\"doi\":\"10.1186/2050-6511-14-57\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Studies have shown that statins have pleiotropic effects on inflammation and coagulation; which may affect the risk of developing venous thromboembolism (VTE). The objective of this study was to evaluate the association between statin therapy during intensive care unit (ICU) stay and the incidence of VTE in critically ill patients.</p><p><strong>Methods: </strong>This was a post-hoc analysis of a prospective observational cohort study of patients admitted to the intensive care unit between July 2006 and January 2008 at a tertiary care medical center. The primary endpoint was the incidence of VTE during ICU stay up to 30 days. Secondary endpoint was overall 30-day hospital mortality. Propensity score was used to adjust for clinically and statistically relevant variables.</p><p><strong>Results: </strong>Of the 798 patients included in the original study, 123 patients (15.4%) received statins during their ICU stay. Survival analysis for VTE risk showed that statin therapy was not associated with a reduction of VTE incidence (crude hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.28-1.54, P=0.33 and adjusted HR 0.63, 95% CI 0.25-1.57, P=0.33). Furthermore, survival analysis for hospital mortality showed that statin therapy was not associated with a reduction in hospital mortality (crude HR 1.26, 95% CI 0.95-1.68, P=0.10 and adjusted HR 0.98, 95% CI 0.72-1.36, P=0.94).</p><p><strong>Conclusion: </strong>Our study showed no statistically significant association between statin therapy and VTE risk in critically ill patients. This question needs to be further studied in randomized control trials.</p>\",\"PeriodicalId\":48846,\"journal\":{\"name\":\"BMC Pharmacology & Toxicology\",\"volume\":\"14 \",\"pages\":\"57\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2013-11-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1186/2050-6511-14-57\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Pharmacology & Toxicology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/2050-6511-14-57\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pharmacology & Toxicology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/2050-6511-14-57","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2
摘要
背景:研究表明他汀类药物对炎症和凝血有多效作用;这可能会影响发生静脉血栓栓塞(VTE)的风险。本研究的目的是评估重症监护病房(ICU)期间他汀类药物治疗与危重患者静脉血栓栓塞发生率之间的关系。方法:这是一项前瞻性观察队列研究的事后分析,研究对象是2006年7月至2008年1月在一家三级医疗中心重症监护病房住院的患者。主要终点是ICU住院30天内静脉血栓栓塞的发生率。次要终点是30天住院总死亡率。倾向评分用于调整临床和统计相关变量。结果:纳入原始研究的798例患者中,123例(15.4%)患者在ICU住院期间接受了他汀类药物治疗。静脉血栓栓塞风险的生存分析显示,他汀类药物治疗与静脉血栓栓塞发生率的降低无关(粗风险比(HR) 0.66, 95%可信区间(CI) 0.28-1.54, P=0.33;校正风险比(HR) 0.63, 95% CI 0.25-1.57, P=0.33)。此外,住院死亡率的生存分析显示,他汀类药物治疗与住院死亡率的降低无关(粗风险比1.26,95% CI 0.95-1.68, P=0.10,校正风险比0.98,95% CI 0.72-1.36, P=0.94)。结论:我们的研究显示他汀类药物治疗与危重患者静脉血栓栓塞风险之间无统计学意义的关联。这个问题需要在随机对照试验中进一步研究。
The association between statin therapy during intensive care unit stay and the incidence of venous thromboembolism: a propensity score-adjusted analysis.
Background: Studies have shown that statins have pleiotropic effects on inflammation and coagulation; which may affect the risk of developing venous thromboembolism (VTE). The objective of this study was to evaluate the association between statin therapy during intensive care unit (ICU) stay and the incidence of VTE in critically ill patients.
Methods: This was a post-hoc analysis of a prospective observational cohort study of patients admitted to the intensive care unit between July 2006 and January 2008 at a tertiary care medical center. The primary endpoint was the incidence of VTE during ICU stay up to 30 days. Secondary endpoint was overall 30-day hospital mortality. Propensity score was used to adjust for clinically and statistically relevant variables.
Results: Of the 798 patients included in the original study, 123 patients (15.4%) received statins during their ICU stay. Survival analysis for VTE risk showed that statin therapy was not associated with a reduction of VTE incidence (crude hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.28-1.54, P=0.33 and adjusted HR 0.63, 95% CI 0.25-1.57, P=0.33). Furthermore, survival analysis for hospital mortality showed that statin therapy was not associated with a reduction in hospital mortality (crude HR 1.26, 95% CI 0.95-1.68, P=0.10 and adjusted HR 0.98, 95% CI 0.72-1.36, P=0.94).
Conclusion: Our study showed no statistically significant association between statin therapy and VTE risk in critically ill patients. This question needs to be further studied in randomized control trials.
期刊介绍:
BMC Pharmacology and Toxicology is an open access, peer-reviewed journal that considers articles on all aspects of chemically defined therapeutic and toxic agents. The journal welcomes submissions from all fields of experimental and clinical pharmacology including clinical trials and toxicology.